Episode 82: Integrating Sustainability Into Biopharma Strategy

Elaine Quilici

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Sandor Schoichet, an independent advisor and director of Meridian Management Consultants based in San Francisco, and Thomas Scheiwiller, an independent advisor and board member based in Zurich, talk about integrating environmental, social, and governance, or ESG, issues into biopharma business planning, and communicating with capital investors about these areas.

Sandor Schoichet, an independent advisor, and director of Meridian Management Consultants based in San Francisco, and Pharm Exec’s Sustainability columnist, and his co-collaborator, Thomas Scheiwiller, an independent advisor and board member based in Zurich, discuss many of the topics we touch on today in regard to biopharma’s approach to integrating environmental, social, and governance, or ESG, issues into business strategy.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.